Company intelligence / Profile preview

Cardiolink

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Cardiolink Science specializes in minimally invasive interventional medical devices with a strong focus on oncology interventions such as TACE. The company holds 19 NMPA registrations and claims the most comprehensive TACE full-solution platform in China. Its product portfolio covers peripheral, coronary, and neurointerventions. Clinical results are not detailed publicly but the company has commercialized multiple device products domestically and begun international expansion.

Therapeutic areas: CardiovascularOncologyNeurology
Modalities: DeviceRadiopharmaceuticals and diagnostic agent
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Cardiolink.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiolink.

Explore the full profile